AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2015
Jan 28, 2015
29864_dirs_2015-01-28_1de03d21-f6f9-4148-bb21-f4dbae180759.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2015-01-26
Reporting Person: Silva Paul M (SVP & Corp Controller)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-01-26 | Common Stock | M | 1125 | $48.74 | Acquired | 18312 | Direct |
| 2015-01-26 | Common Stock | S | 725 | $125.26 | Disposed | 17587 | Direct |
| 2015-01-26 | Common Stock | S | 400 | $126.27 | Disposed | 17187 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-01-26 | Stock Option (right to buy) | $48.74 | M | 1125 | Disposed | 2022-07-24 | Common Stock (1125) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 169 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $125.26 (range $124.99 to $125.83).
F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $126.27 (range $126.00 to $126.56).
F5: The option vests in 16 quarterly installments from 07/25/2012.